Study of Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma
N/A
N/A
Both
Melanoma
Trial Information
Study of Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma
Patients with melanoma can succumb to subclinical metastatic disease, not detectable at
presentation by conventional physical examination, hematologic and biochemical screening, or
radiologic evaluation. More intensive radiologic evaluation with CT or radioisotope scanning
has not proven to be useful. What may be useful is a more sensitive method of staging
melanoma patients at presentation, specifically evaluating them for subclinical systemic
disease.
Inclusion Criteria:
MSK Patients with histologically confirmed melanoma of any site and at least one of the
following:
- Primary tumor > 4.0 mm thick (AJCC Stage IIB)
- Clinically or histologically positive regional nodes (AJCC Stage III)
- Any in transit disease (AJCC Stage III)
- Any systemic metastases (AJCC Stage IV)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Assess the sensitivity of RT-PCR to detect evidence of melanoma cells in bone marrow and/or peripheral blood and estimate sensitivity separately for each of the different stage groupings for melanoma
Outcome Time Frame:
2 years
Safety Issue:
No
Principal Investigator
Danile Coit, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
91-125
NCT ID:
NCT00588198
Start Date:
October 1991
Completion Date:
September 2009
Related Keywords:
- Melanoma
- histologically confirmed melanoma of any site
- Melanoma
- Neoplasm Metastasis
Name | Location |
|---|---|
| Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
